Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
Aliment Pharmacol Ther 2011; 33: 138–148 Summary Background Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C. Aim To validate and compare the diagnostic performance of non‐invasive tests for prediction of liver fibrosis severity and assessed changes in extrace...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2011-01, Vol.33 (1), p.138-148 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 148 |
|---|---|
| container_issue | 1 |
| container_start_page | 138 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 33 |
| creator | Martinez, S. M. Fernández‐Varo, G. González, P. Sampson, E. Bruguera, M. Navasa, M. Jiménez, W. Sánchez‐Tapias, J. M. Forns, X. |
| description | Aliment Pharmacol Ther 2011; 33: 138–148
Summary
Background Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C.
Aim To validate and compare the diagnostic performance of non‐invasive tests for prediction of liver fibrosis severity and assessed changes in extracellular matrix markers after antiviral treatment.
Methods The performances of Forns’ score, AST to platelet ratio index (APRI), FIB‐4 index and Enhanced Liver Fibrosis (ELF) score were validated in 340 patients who underwent antiviral therapy. These scores were determined 24 weeks after treatment in 161 patients.
Results Forns’ score, APRI, FIB‐4 and ELF score showed comparable diagnostic accuracies for significant fibrosis [area under the receiver operating characteristic curve (AUROC) 0.83, 0.83, 0.85 and 0.81, respectively]. To identify cirrhosis, FIB‐4 index showed a significantly better performance over APRI and ELF score (AUROC 0.89 vs. 0.83 and 0.82, respectively). ELF score decreased significantly in patients with sustained virological response (SVR) (P |
| doi_str_mv | 10.1111/j.1365-2036.2010.04500.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00599491v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>816385695</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5140-5c494c81b8eebc1b05dd5ac3b0c668f8af7dd8d883005ed0c991e072091725d63</originalsourceid><addsrcrecordid>eNqNkctuEzEUhkcIREPhFZA3CLGYcGyPPfaCRRS1FCkSLMra8viicZhLsCdp8wC8dz0khCV446Pzf-di_0WBMCxxPh-3S0w5KwlQviSQs1AxgOXjs2JxEZ4XCyBclkRgelW8SmkLALwG8rK4IhgEZUIuil-rlFxKvRsmNHrUhYOLyIcmjikk1Dg_Rof0YJH2U1b0MIVDiLpDU-ui3h1Rc0Q2eO_i3CG5uO9Rr-OPzO704LqEwpCjKWQ5oYcwtci0cRyCQa2b81Mes35dvPC6S-7N-b4uvt_e3K_vys3Xz1_Wq01pGK6gZKaSlRG4Ec41BjfArGXa0AYM58IL7WtrhRWCAjBnwUiJHdQEJK4Js5xeFx9OfVvdqV0MedOjGnVQd6uNmnO5TspK4gPO7PsTu4vjz71Lk-pDMq7r8rPGfVKi5oQwwap_k5hTwbhkmRQn0uT_TdH5yxIY1Oys2qrZQDUbqGZn1W9n1WMufXsesm96Zy-Ff6zMwLszoJPRnY96MCH95SgnVEjI3KcT9xA6d_zvBdTq2_0c0SfEIb-a</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>816385695</pqid></control><display><type>article</type><title>Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Martinez, S. M. ; Fernández‐Varo, G. ; González, P. ; Sampson, E. ; Bruguera, M. ; Navasa, M. ; Jiménez, W. ; Sánchez‐Tapias, J. M. ; Forns, X.</creator><creatorcontrib>Martinez, S. M. ; Fernández‐Varo, G. ; González, P. ; Sampson, E. ; Bruguera, M. ; Navasa, M. ; Jiménez, W. ; Sánchez‐Tapias, J. M. ; Forns, X.</creatorcontrib><description>Aliment Pharmacol Ther 2011; 33: 138–148
Summary
Background Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C.
Aim To validate and compare the diagnostic performance of non‐invasive tests for prediction of liver fibrosis severity and assessed changes in extracellular matrix markers after antiviral treatment.
Methods The performances of Forns’ score, AST to platelet ratio index (APRI), FIB‐4 index and Enhanced Liver Fibrosis (ELF) score were validated in 340 patients who underwent antiviral therapy. These scores were determined 24 weeks after treatment in 161 patients.
Results Forns’ score, APRI, FIB‐4 and ELF score showed comparable diagnostic accuracies for significant fibrosis [area under the receiver operating characteristic curve (AUROC) 0.83, 0.83, 0.85 and 0.81, respectively]. To identify cirrhosis, FIB‐4 index showed a significantly better performance over APRI and ELF score (AUROC 0.89 vs. 0.83 and 0.82, respectively). ELF score decreased significantly in patients with sustained virological response (SVR) (P < 0.0001) but remained unchanged in nonresponders. Non‐1 hepatitis C virus (HCV) genotype, baseline lower HCV RNA, glucose, hyaluronic acid and higher cholesterol levels were independently associated with SVR.
Conclusions Simple panel markers and ELF score are accurate at identifying significant fibrosis and cirrhosis in chronic hepatitis C. A decrease in ELF score after antiviral treatment reflects the impact of viral clearance in hepatic extracellular matrix and probably in the improvement of liver fibrosis.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2010.04500.x</identifier><identifier>PMID: 21083589</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Biomarkers - blood ; Biopsy ; Cholesterol ; Cirrhosis ; Digestive system ; Epidemiologic Methods ; Extracellular matrix ; Female ; Fibrosis ; Gastroenterology. Liver. Pancreas. Abdomen ; Genotypes ; Glucose ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Human viral diseases ; Humans ; Hyaluronic acid ; Infectious diseases ; Interferon-alpha - therapeutic use ; Liver ; Liver - pathology ; Liver Cirrhosis - blood ; Liver Cirrhosis - drug therapy ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Platelet Count ; Platelets ; Recombinant Proteins ; Ribavirin - therapeutic use ; RNA ; Viral diseases ; Viral hepatitis ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (1), p.138-148</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><rights>2010 Blackwell Publishing Ltd.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5140-5c494c81b8eebc1b05dd5ac3b0c668f8af7dd8d883005ed0c991e072091725d63</citedby><cites>FETCH-LOGICAL-c5140-5c494c81b8eebc1b05dd5ac3b0c668f8af7dd8d883005ed0c991e072091725d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2010.04500.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2010.04500.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23623890$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21083589$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00599491$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinez, S. M.</creatorcontrib><creatorcontrib>Fernández‐Varo, G.</creatorcontrib><creatorcontrib>González, P.</creatorcontrib><creatorcontrib>Sampson, E.</creatorcontrib><creatorcontrib>Bruguera, M.</creatorcontrib><creatorcontrib>Navasa, M.</creatorcontrib><creatorcontrib>Jiménez, W.</creatorcontrib><creatorcontrib>Sánchez‐Tapias, J. M.</creatorcontrib><creatorcontrib>Forns, X.</creatorcontrib><title>Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aliment Pharmacol Ther 2011; 33: 138–148
Summary
Background Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C.
Aim To validate and compare the diagnostic performance of non‐invasive tests for prediction of liver fibrosis severity and assessed changes in extracellular matrix markers after antiviral treatment.
Methods The performances of Forns’ score, AST to platelet ratio index (APRI), FIB‐4 index and Enhanced Liver Fibrosis (ELF) score were validated in 340 patients who underwent antiviral therapy. These scores were determined 24 weeks after treatment in 161 patients.
Results Forns’ score, APRI, FIB‐4 and ELF score showed comparable diagnostic accuracies for significant fibrosis [area under the receiver operating characteristic curve (AUROC) 0.83, 0.83, 0.85 and 0.81, respectively]. To identify cirrhosis, FIB‐4 index showed a significantly better performance over APRI and ELF score (AUROC 0.89 vs. 0.83 and 0.82, respectively). ELF score decreased significantly in patients with sustained virological response (SVR) (P < 0.0001) but remained unchanged in nonresponders. Non‐1 hepatitis C virus (HCV) genotype, baseline lower HCV RNA, glucose, hyaluronic acid and higher cholesterol levels were independently associated with SVR.
Conclusions Simple panel markers and ELF score are accurate at identifying significant fibrosis and cirrhosis in chronic hepatitis C. A decrease in ELF score after antiviral treatment reflects the impact of viral clearance in hepatic extracellular matrix and probably in the improvement of liver fibrosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biopsy</subject><subject>Cholesterol</subject><subject>Cirrhosis</subject><subject>Digestive system</subject><subject>Epidemiologic Methods</subject><subject>Extracellular matrix</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Genotypes</subject><subject>Glucose</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Count</subject><subject>Platelets</subject><subject>Recombinant Proteins</subject><subject>Ribavirin - therapeutic use</subject><subject>RNA</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctuEzEUhkcIREPhFZA3CLGYcGyPPfaCRRS1FCkSLMra8viicZhLsCdp8wC8dz0khCV446Pzf-di_0WBMCxxPh-3S0w5KwlQviSQs1AxgOXjs2JxEZ4XCyBclkRgelW8SmkLALwG8rK4IhgEZUIuil-rlFxKvRsmNHrUhYOLyIcmjikk1Dg_Rof0YJH2U1b0MIVDiLpDU-ui3h1Rc0Q2eO_i3CG5uO9Rr-OPzO704LqEwpCjKWQ5oYcwtci0cRyCQa2b81Mes35dvPC6S-7N-b4uvt_e3K_vys3Xz1_Wq01pGK6gZKaSlRG4Ec41BjfArGXa0AYM58IL7WtrhRWCAjBnwUiJHdQEJK4Js5xeFx9OfVvdqV0MedOjGnVQd6uNmnO5TspK4gPO7PsTu4vjz71Lk-pDMq7r8rPGfVKi5oQwwap_k5hTwbhkmRQn0uT_TdH5yxIY1Oys2qrZQDUbqGZn1W9n1WMufXsesm96Zy-Ff6zMwLszoJPRnY96MCH95SgnVEjI3KcT9xA6d_zvBdTq2_0c0SfEIb-a</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Martinez, S. M.</creator><creator>Fernández‐Varo, G.</creator><creator>González, P.</creator><creator>Sampson, E.</creator><creator>Bruguera, M.</creator><creator>Navasa, M.</creator><creator>Jiménez, W.</creator><creator>Sánchez‐Tapias, J. M.</creator><creator>Forns, X.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>201101</creationdate><title>Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C</title><author>Martinez, S. M. ; Fernández‐Varo, G. ; González, P. ; Sampson, E. ; Bruguera, M. ; Navasa, M. ; Jiménez, W. ; Sánchez‐Tapias, J. M. ; Forns, X.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5140-5c494c81b8eebc1b05dd5ac3b0c668f8af7dd8d883005ed0c991e072091725d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biopsy</topic><topic>Cholesterol</topic><topic>Cirrhosis</topic><topic>Digestive system</topic><topic>Epidemiologic Methods</topic><topic>Extracellular matrix</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Genotypes</topic><topic>Glucose</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Count</topic><topic>Platelets</topic><topic>Recombinant Proteins</topic><topic>Ribavirin - therapeutic use</topic><topic>RNA</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martinez, S. M.</creatorcontrib><creatorcontrib>Fernández‐Varo, G.</creatorcontrib><creatorcontrib>González, P.</creatorcontrib><creatorcontrib>Sampson, E.</creatorcontrib><creatorcontrib>Bruguera, M.</creatorcontrib><creatorcontrib>Navasa, M.</creatorcontrib><creatorcontrib>Jiménez, W.</creatorcontrib><creatorcontrib>Sánchez‐Tapias, J. M.</creatorcontrib><creatorcontrib>Forns, X.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinez, S. M.</au><au>Fernández‐Varo, G.</au><au>González, P.</au><au>Sampson, E.</au><au>Bruguera, M.</au><au>Navasa, M.</au><au>Jiménez, W.</au><au>Sánchez‐Tapias, J. M.</au><au>Forns, X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2011-01</date><risdate>2011</risdate><volume>33</volume><issue>1</issue><spage>138</spage><epage>148</epage><pages>138-148</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aliment Pharmacol Ther 2011; 33: 138–148
Summary
Background Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C.
Aim To validate and compare the diagnostic performance of non‐invasive tests for prediction of liver fibrosis severity and assessed changes in extracellular matrix markers after antiviral treatment.
Methods The performances of Forns’ score, AST to platelet ratio index (APRI), FIB‐4 index and Enhanced Liver Fibrosis (ELF) score were validated in 340 patients who underwent antiviral therapy. These scores were determined 24 weeks after treatment in 161 patients.
Results Forns’ score, APRI, FIB‐4 and ELF score showed comparable diagnostic accuracies for significant fibrosis [area under the receiver operating characteristic curve (AUROC) 0.83, 0.83, 0.85 and 0.81, respectively]. To identify cirrhosis, FIB‐4 index showed a significantly better performance over APRI and ELF score (AUROC 0.89 vs. 0.83 and 0.82, respectively). ELF score decreased significantly in patients with sustained virological response (SVR) (P < 0.0001) but remained unchanged in nonresponders. Non‐1 hepatitis C virus (HCV) genotype, baseline lower HCV RNA, glucose, hyaluronic acid and higher cholesterol levels were independently associated with SVR.
Conclusions Simple panel markers and ELF score are accurate at identifying significant fibrosis and cirrhosis in chronic hepatitis C. A decrease in ELF score after antiviral treatment reflects the impact of viral clearance in hepatic extracellular matrix and probably in the improvement of liver fibrosis.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21083589</pmid><doi>10.1111/j.1365-2036.2010.04500.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (1), p.138-148 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00599491v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antiviral Agents - therapeutic use Biological and medical sciences Biomarkers - blood Biopsy Cholesterol Cirrhosis Digestive system Epidemiologic Methods Extracellular matrix Female Fibrosis Gastroenterology. Liver. Pancreas. Abdomen Genotypes Glucose Hepatitis C Hepatitis C virus Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Human viral diseases Humans Hyaluronic acid Infectious diseases Interferon-alpha - therapeutic use Liver Liver - pathology Liver Cirrhosis - blood Liver Cirrhosis - drug therapy Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Platelet Count Platelets Recombinant Proteins Ribavirin - therapeutic use RNA Viral diseases Viral hepatitis Young Adult |
| title | Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A24%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20liver%20fibrosis%20before%20and%20after%20antiviral%20therapy%20by%20different%20serum%20marker%20panels%20in%20patients%20with%20chronic%20hepatitis%20C&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Martinez,%20S.%20M.&rft.date=2011-01&rft.volume=33&rft.issue=1&rft.spage=138&rft.epage=148&rft.pages=138-148&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2010.04500.x&rft_dat=%3Cproquest_hal_p%3E816385695%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=816385695&rft_id=info:pmid/21083589&rfr_iscdi=true |